Comparative Pharmacology
Head-to-head clinical analysis: KOMBIGLYZE XR versus SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOMBIGLYZE XR versus SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE.
KOMBIGLYZE XR vs SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion, and suppressing glucagon release. Metformin reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and improves insulin sensitivity.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
Initial dose: 2.5 mg saxagliptin/500 mg metformin hydrochloride orally twice daily with meals. Titrate up to max 5 mg/1000 mg twice daily.
None Documented
None Documented
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Saxagliptin: 2.5 hours; 5-hydroxy saxagliptin (active metabolite): 3.1 hours. Metformin: 4.5-6.2 hours. Total combined half-life 2-6 hours, requiring twice-daily dosing.
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Saxagliptin: 75% renal (50% unchanged, 25% as metabolite), 22% fecal. Metformin: 90-100% renal unchanged via tubular secretion.
Category C
Category A/B
DPP-4 Inhibitor + Biguanide Combination
DPP-4 Inhibitor